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RESULTS FROM  
SYSTEMATIC  
LITERATURE REVIEW 
ON PE/E IN NIGERIA
• Pre-eclampsia is a condition               
in pregnant women marked by an 
increase in blood pressure and 
protein in urine after 20 weeks 
gestation.
• Providing high quality antenatal 
care improves the prevention and 
early detection of pre-eclampsia 
and can prevent its progression to 
eclampsia.
• Eclampsia is a life-threatening 
condition characterized by 
convulsions in women with  
pre-eclampsia.
• Women in developing countries 
are 300 times more likely to die 
from eclampsia than women in 
developed countries.
• Prescribing low-dose aspirin and 
calcium to at-risk women can 
lower their risk of developing  
pre-eclampsia and eclampsia.
• Severe pre-eclampsia can be 
managed by administering 
anti-hypertensive drugs and 
magnesium sulphate (MgSO4).
• MgSO4 is the safest and most 
effective treatment for severe 
PE/E. 
• Pre-eclampsia and other 
hypertensive disorders in 
pregnancy increase the risk of pre-
term births, which can lead to low 
birth weight, anemia, and stunting.
• Improved prevention, increased 
detection, and effective treatment 
of PE/E can prevent unnecessary 
maternal and newborn deaths.
PE/E in Brief
BACKGROUND AND INTRODUCTION
Despite significant declines in maternal mortality rates, sub-Saharan Africa 
continues to have a high burden of maternal mortality. Nigeria is one of 10 
countries where women are most at risk of dying during childbirth and is 
responsible for 14 percent of the world’s maternal deaths. 
Pre-eclampsia and eclampsia (PE/E), hypertensive disorders of pregnancy, 
are consistently cited as a leading cause of maternal and newborn morbidity 
and mortality Nigeria. A recent, nationwide cross-sectional survey found 
that PE/E is the leading cause of maternal mortality in Nigeria, contributing 
to 28.2 percent of national maternal deaths. he other main contributors to maternal 
mortality are hemorrhage, at 24.4 percent, and pregnancy-related infection or 
sepsis, at 14.2 percent. 
To fully understand the key challenges, gaps, and interventions related to the 
prevention and treatment of PE/E, the Ending Eclampsia project conducted 
a systematic review of papers on PE/E in Nigeria published between 2000-
2015. The methods, results, and recommendations are discussed below. 
METHODS
Researchers designed two sets of key search terms related to pre-eclampsia 
and eclampsia to capture references for peer-reviewed papers on PE/E 
detection, management, and prevention. The searches were run in the following 
bibliographic databases: PubMed, ScienceDirect, World of Science, Cochrane, 
POPLINE, and Wiley Online Library, as well as google.com. Two independent 
reviewers read and evaluated the results in three phases: Abstract and title 
review, full text review, and categorization of papers (Figure 1). 
In Phase I, reviewers evaluated abstracts to determine relevance. Abstracts 
were excluded if they were: 
1. Not about Nigeria;
2. Not related to pregnancy (e.g. abstracts about male subjects, children, 
epilepsy, and other disorders); or
3. Not related to PE/E or any associated risk factors, symptoms, or compli-
cations. 
The reviewers reconciled their results, and came to a consensus on any 
discrepancies. 
In Phase ll, to confirm the results the reviewers read the full texts of the 
remaining citations to determine relevance and eliminated papers that were 
not related to PE/E, did not primarily focus on Nigeria, or did not provide any 
substantive data specific to Nigeria, and any papers without a full text.  
Finally, the remaining articles were sorted into five categories—based on the 
main topic of each—that were found during the systematic review.
1. Strategies that explored prevention or managment of PE/E;
2. Demonstrated and potential risk factors for pre-eclampsia;
3. Other health outcomes associated with PE/E;
4. Descriptive program summaries and literature reviews; and
5. Record reviews of hospital case files.
The goal was to identify articles with evidence on interventions that addressed 
the prevention, diagnosis, and treatment of PE/E. 
The Ending Eclampsia project seeks to expand 
access to proven,underutilized interventions and 
commodities for the prevention, early detection, 
and treatment of pre-eclampsia and eclampsia and 
strengthen global partnerships. 
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RESULTS
After removing duplicate citations and those unrelated 
to this review, 520 abstracts were included in Phase I. 
The reviewers removed 338 articles that were deemed 
to not fulfill the inclusion requirements for Phase I. 
During Phase II, 37 articles were removed as they did not 
provide enough, relevant Nigeria-specific information or if 
a full text document could not be located. The systematic 
review included 145 articles. 
Five major themes emerged from the reviewed articles: 
Strategies for prevention and treatment of PE/E, 
demonstrated and potential risk factors, other health 
outcomes associated with PE/E, program descriptions 
and literature reviews, and hospital record reviews.
Strategies for prevention and management
Nineteen papers discussed strategies for detecting, 
monitoring, and managing PE/E. The overarching findings 
revealed effective case management occurs continually, 
from detection to after delivery. Early management of 
PE (before 30 weeks), using detailed monitoring charts 
that allow providers to document patients’ health and 
treatment4, and institutionalizing updated policies and 
guidelines improve of quality care for women with PE/E.
Another strategy is early management of PE, incorporating 
a tool that streamlines monitoring and treatment, and 
another tests the role of serum magnesium levels in 
eclamptic patients as a way to test for MgSO4 toxicity.
Four articles questioned the standard dosing regimen 
for MgSO4 and suggested that the favored Pritchard 
Regimen - four grams MgSO4 IV, five grams in each 
buttock, followed by five grams in atlernate buttocks for 
24 hours - may be excessive, and proposed that reducing 
FIGURE 1: Flow Chart of Review Process the amount or frequency of doses may be as effective 
and safe as the currently-accepted standard. 
The literature indicates that cesarean section (CS), 
conducted using spinal anesthesia, is likely the safest 
mode of delivery for PE/E cases. However, if treatment is 
successful, a woman can still delivery her baby vaginally. 
While each of these strategies can potentially reduce 
mortality due to PE/E, the most essential strategy 
focuses on improving providers’ knowledge and skills for 
detecting and managing obstetric emergencies, including 
task shifting to primary facility providers.
Demonstrated and potential risk factors
While the biological mechanism for developing pre-
eclampsia remains unknown, many studies looked at 
various attributes or conditions in an effort to confirm 
or identify potential risk factors for developing PE/E. 
Previously demonstrated risk factors for PE/E that appear 
in the literature include low parity, young age, multiple 
gestation, history of chronic high blood pressure (BP), 
previous PE, and no antenatal care (ANC) visits. 
Most of the articles investigated potential risk factors 
relating to biomarkers in pregnancy. Various biological 
measures were examined to determine if there were 
observable trends or associations between the 
biomarker and the development of PE/E. The literature 
seems to indicate that elevated levels of haptoglobin, 
malondialdehyde, phenylalanine concentration, blood 
lead and homocysteine levels may contribute to the 
development of PE/E. Similarly, low serum concentrations 
of zinc, copper, manganese and magnesium, and low 
plasma calcium, vitamin C, and E could also indicate pre-
eclampsia or risk of pre-eclampsia in pregnant women.
Other potential risk factors explored in the literature were 
change in paternity, maternal ethnicity, and sickle cell 
anemia, though many studies were unable to draw firm 
conclusions due to small sample sizes.
Other health outcomes
Women who experience PE/E are at increased risk 
of cesarean section (CS), cardiac complications, and 
chronic hypertension. Among the less-common outcomes 
reported, there were orofacial injuries and loss of vision. 
One article named paralysis as an outcome for one 
patient, but did not provide clear etiology.
Another outcome of PE/E is HELLP syndrome, a 
dangerous condition that complicates eclampsia with 
hemolysis, elevated liver enzymes, and low platelets. 
HELLP syndrome causes internal organs to shut down, 
and if left untreated, the mother’s and fetus’ health, 
will deteriorate and can lead to death. In addition to the 
immediate maternal health outcomes, other newborn 
health outcomes associated with PE/E are preterm birth, 




Despite the wealth of information in the literature on PE/E 
in Nigeria, gaps remain and require further research. 
Gaps in Prevention of PE/E
Globally, aspirin and calcium are thought to have a 
protective effect for women at risk of PE/E. This is briefly 
mentioned without supportive evidence on the incidence 
of PE/E. The effectiveness and impact of prophylactic 
aspirin and calcium are unknown in the Nigerian context.
Gaps in Detection of PE/E
Gaps affecting detection of PE/E include unclear 
terminology and clinical definitions and low antenatal 
care (ANC) attendance. Even when ANC is given, providers 
and families are unaware of signs and symptoms of PE/E. 
There is no consistency in terminology used or in clinical 
definitions for those terms; each paper provides their 
own definitions with some overlapping diagnosis criteria 
for BP levels, proteinuria and other symptoms including 
edema, headache, and visual disturbances.
The literature shows patients “booked” for ANC are less 
likely to develop PE/E compared to “unbooked” women 
but what the literature doesn’t show are details about 
which services women receive during ANC and whether 
or not they are counselled on danger signs in pregnancy. 
Gaps in Management of PE/E
The literature supports use of MgSO4 to manage severe 
pre-eclampsia and eclampsia, but the lowest effective 
dose is unknown. The current literature omits the utility 
of antihypertensive drugs to manage high BP in pregnant 
women, which is a strategy to reduce the risk of stroke.
Despite the evidence demonstrating the safety and 
effectiveness of MgSO4, its use remains low due to poor 
availability, inadequate knowledge among communities , 
lack of guidelines on its use (or unawareness of these 
guidelines), misinformation regarding who can administer 
the drug, poor knowledge of health workers on its use, fear 
of toxicity, little incentive for pharmaceutical companies 
to commercialize the drug (no return on investment), 
availability of less effective drugs (like diazepam), and 
lack of support for policy change all contribute to the 
underutilization of this safe and effective life-saving drug.
In addition to the relatively low use of MgSO4, there are 
no studies that demonstrate the lowest effective dose 
to manage PE/E. Some researchers have started 
questioning and testing the dosage with preliminary 
results indicating that a reduced dose—either in amount 
delivered or timing of doses—can be as effective as the 
generally-accepted Pritchard regimen.
For the full report, visit www.endingeclampsia.org
Suggested citation: Kirk, Karen R. & Ishita Chattopadhyay. 
2015. “A systematic review of the treatment and management 
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CONCLUSION AND RECOMMENDATIONS
Throughout the development of a pregnancy, there 
are many opportunities when PE/E can be prevented, 
detected and managed; however, based on the literature, 
certain gaps exist along this continuum of care. 
In order to have the greatest impact, we recommend a 
multi-level set of interventions that increase community 
awareness of symptoms of PE/E and ANC health seeking 
behavior, improve and expand provider skills and 
knowledge at multiple levels (including primary health 
centers) for detecting and treating high BP in pregnancy 
and PE/E throughout the developmental stages of 
pregnancy. 
To reduce the mortality associated with PE/E in Nigeria, 
the global community and national stakeholders must:
Develop a common language and streamlined policies: 
• Develop simple terminology and associated  
definitions for global use.
• Advocate to hospital administrators and relevant 
policymakers to ensure adherence to management 
protocols and procurement of essential drugs.
Clarify and define management strategies and dosage:
• Determine minimum effective dose for MgSO4.
• Create and distribute clear and concise guidelines 
and protocols for managing hypertension and PE/E 
with antihypertensives and MgSO4.
• Assess the impact of aspirin and/or calcium  
prophylaxis in Nigeria.
Increase access to quality services:
• Train and maintain healthcare providers on  
recognizing PE/E, managing high BP with  
antihypertensive drugs, when and how to adminis-
ter MgSO4, and how to monitor for and treat  
MgSO4 toxicity.
• Train PHC providers to detect and provide initial 
treatment (antihypertensives and MgSO4 loading 
dose) for PE/E and refer to secondary facilities.
Engage Community:
• Increase community awareness and access to ANC. 
• Educate community members on signs and  
symptoms of PE/E and when and where to seek 
treatment.
